Issue navigation
Volume 28, Issue 10, October 2022
Leading Off
Epidemiology and Natural History of Perianal Crohn’s Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1477–1484, https://doi.org/10.1093/ibd/izab287
Molecular Network Analyses Implicate Death-Associated Protein Kinase 3 (DAPK3) as a Key Factor in Colitis-Associated Dysplasia Progression
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1485–1496, https://doi.org/10.1093/ibd/izac098
Clinical Research
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1497–1505, https://doi.org/10.1093/ibd/izab302
Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1506–1512, https://doi.org/10.1093/ibd/izab301
This prospective single-center study on 602 inflammatory bowel disease (IBD) patients and 168 healthy controls shows that vaccination against COVID-19 is effective and safe in patients with IBD. It warrants particular attention to the anti-SARS-CoV-2 vaccination of IBD patients treated with TNF-α inhibitors with immunomodulators, shows priority of mRNA vaccines in this specific group of patients, and confirms that IBD patients can continue their high-efficacy immune-modifying therapy, including biological treatment, even during the anti-SARS-CoV-2 vaccination.
Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1513–1519, https://doi.org/10.1093/ibd/izab299
Association Between Inflammatory Bowel Disease and Dementia: A Longitudinal Cohort Study
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1520–1526, https://doi.org/10.1093/ibd/izab300
The Magnitude of Crohn’s Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1527–1536, https://doi.org/10.1093/ibd/izab334
Quantification of Mucosal Activity from Colonoscopy Reports via the Simplified Endoscopic Mucosal Assessment for Crohn’s Disease
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1537–1542, https://doi.org/10.1093/ibd/izab315
Causal Association Between Atopic Dermatitis and Inflammatory Bowel Disease: A 2-Sample Bidirectional Mendelian Randomization Study
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1543–1548, https://doi.org/10.1093/ibd/izab329
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1549–1554, https://doi.org/10.1093/ibd/izab328
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1555–1564, https://doi.org/10.1093/ibd/izab310
Health Confidence Is Associated With Disease Outcomes and Health Care Utilization in Inflammatory Bowel Disease: A Nationwide Cross-sectional Study
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1565–1572, https://doi.org/10.1093/ibd/izab313
Low health confidence is highly correlated with more health care utilization (ambulatory and acute hospital-based care), worse disease activity, more opioid and glucocorticoid use, and poorer well-being in a large, nationwide sample of adults with inflammatory bowel disease (IBD) in diverse settings.
Basic Science Research
A Systematic Review of Artificial Intelligence and Machine Learning Applications to Inflammatory Bowel Disease, with Practical Guidelines for Interpretation
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1573–1583, https://doi.org/10.1093/ibd/izac115
Clinical Review
Microscopic Colitis Is Associated With a Reduced Risk of Colorectal Adenoma and Cancer: A Meta-Analysis
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1584–1591, https://doi.org/10.1093/ibd/izab333
Basic Science Review
Use and Misuse of Parenteral Nutrition in Patients with Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1592–1602, https://doi.org/10.1093/ibd/izac085
Clinical Brief Reports
Normal Sperm DNA Integrity in Patients With Inflammatory Bowel Disease on Ustekinumab Maintenance Therapy
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1603–1606, https://doi.org/10.1093/ibd/izac028
Balsalazide Exposure During the Development of Fertilizing Sperm May Be Associated With Offspring Birth Defects
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1607–1609, https://doi.org/10.1093/ibd/izac038
Vancomycin Is Effective in the Treatment of Chronic Inflammatory Conditions of the Pouch
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1610–1613, https://doi.org/10.1093/ibd/izac043
Natural History of New-onset Inflammatory Bowel Disease Among Patients With Multiple Sclerosis
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1614–1617, https://doi.org/10.1093/ibd/izac053
Association Between the Clinical, Biochemical, and Endoscopic Activity of Inflammatory Bowel Diseases and Severity and Long-term Outcomes of Coronavirus Disease 2019—A Population-based Study
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1618–1622, https://doi.org/10.1093/ibd/izac052
Case Report
De Novo Pediatric Ulcerative Colitis Triggered by SARS-CoV-2 Infection: a Tale of 2 Sisters
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages 1623–1625, https://doi.org/10.1093/ibd/izac142
Letters to the Editor
Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: A Survey From China
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages e134–e136, https://doi.org/10.1093/ibd/izac118
Should a Psychologist Be a Mandatory Component of Inflammatory Bowel Disease Consults? Yes
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Page e137, https://doi.org/10.1093/ibd/izac123
Should a Psychologist Be a Mandatory Component of IBD Consults? Yes—Authors' Reply
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages e138–e139, https://doi.org/10.1093/ibd/izac125
Patient With Ulcerative Colitis and Failure of Ustekinumab Responds to Risankizumab: Similar Is Not Identical
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Pages e140–e141, https://doi.org/10.1093/ibd/izac072
Correspondence on “Immunogenicity of COVID-19 Vaccine Doses in Patients With Inflammatory Bowel Disease”
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Page e142, https://doi.org/10.1093/ibd/izac108
Corrections
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Page e143, https://doi.org/10.1093/ibd/izac066
Correction to: Association Between Inflammatory Bowel Disease and Dementia: A Longitudinal Cohort Study
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Page e144, https://doi.org/10.1093/ibd/izac155
Correction to: Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
Inflammatory Bowel Diseases, Volume 28, Issue 10, October 2022, Page e145, https://doi.org/10.1093/ibd/izac163
